The Food and Drug Administration on Monday approved Biogen’s new Alzheimer’s drug, a decision with far-reaching implications for patients, clinicians, and others. Here’s a rundown on some basic questions and answers about the drug, known as Aduhelm.
Who can get the drug?
The drug is approved for patients with early-stage Alzheimer’s who are experiencing mild cognitive impairment. Those with advanced Alzheimer’s will not be candidates for the drug.